A new report by the RAND Corporation estimates the potential future cost savings gained from the use of biosimilars in the United States at $54 billion over 10 years, and examines future policy issues surrounding this important market.
In the 7 years since the enactment of the Biologics Price Competition and Innovation Act (BCPIA), which authorized the FDA to create a new regulatory approval pathway for biosimilars, the agency has approved 7 biosimilars, 3 of which have been marketed. The BCPIA’s biosimilar approval pathway was designed to promote competition among drug manufacturers in order to lower prices and potentially increase access to medications.
Although the US biosimilars market is still in its infancy, there are over 60 biosimilar molecules in development for more than 20 reference biologics. A new report by the RAND Corporation, “Biosimilar Cost Savings in the United States: Initial Experience and Future Potential,” estimates the potential future cost savings gained from the use of biosimilars in the United States at $54 billion over 10 years, and examines future policy issues surrounding this important market. The research described in the RAND report was sponsored by Sandoz.
The report concludes that:
Forecasting the future of the US biosimilars market, the RAND report suggests that evolving payment arrangements, regulatory policies and guidance, patient and prescriber acceptance of biosimilars, and other factors will influence the magnitude of potential savings. Other drivers of spending on biosimilar drugs work with and through competition to determine biosimilars’ market share, prices, and impact on spending, the report explains: “We identified competition as the most important factor in determining impact on spending.”
The report outlines the most important features of the still-evolving biosimilars market:
The RAND report notes that the potential for cost savings will vary across biologic classes based on sales, degree of competition, and timing of biosimilar entry. Anti—tumor necrosis factor (TNF) products, monoclonal antibody antineoplastics, and immunostimulants excluding interferons alone account for 87% of estimated savings from biosimilars. (The anti–TNF agent category includes some of the largest biologic products by sales and biosimilars that are already marketed or close to market entry.)
The Future of the US Biosimilars Market
Several key challenges and sources of uncertainty concerning the US biosimilar market remain, including questions about whether the market is sustainable or will lead to the intended cost savings. In addition to the issue of interchangeability, price competition will be affected by non-price competition from reference biologic manufacturers because biologic manufacturers in some markets are developing next-generation biologics that offer improvements over older reference biologics facing potential biosimilar competition. These next-generation biologics will compete with biosimilars and older reference biologics for market share. In addition, biosimilar naming conventions using a distinguishing 4-letter suffix may affect perceptions and acceptance of biosimilars—prescribers and patients could perceive lower efficacy or different safety for biosimilars and avoid their use.
Finally, the RAND report presents US policymakers with 2 choices going forward: they can allow the market to continue to develop under current policies—for example, allowing increasing FDA and industry experience with approval requirements, building on an understanding of legal issues set through early Court decisions, and allowing evolving pricing and market-share trends to eventually provide clarity on the stability of the US biosimilar market. Alternatively, they can intervene and help steer the US biosimilars market more quickly to a sustainable, competitive state, for example, reworking Medicare’s drug payment policies to more actively incentivize biosimilar uptake by lowering or eliminating cost sharing for biosimilars.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.